133 related articles for article (PubMed ID: 2420725)
1. [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
Naber KG; Adam D; Wittenberger R; Bartosik-Wich B
Infection; 1986; 14 Suppl 1():S60-4. PubMed ID: 2420725
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients.
Naber KG; Adam D; Kees F
Drugs; 1987; 34 Suppl 1():44-50. PubMed ID: 3481328
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
Infection; 1985; 13(5):219-24. PubMed ID: 2933340
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
Infection; 1986; 14 Suppl 3():S203-8. PubMed ID: 3463543
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ofloxacin and norfloxacin concentration in prostatic tissues in patients undergoing transurethral resection of the prostate.
Chen J; Chen RR; Huang HS
J Formos Med Assoc; 2001 Aug; 100(8):548-52. PubMed ID: 11678006
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of ofloxacin against complicated urinary tract infections].
Nishio S; Yoshihara H
Hinyokika Kiyo; 1987 Sep; 33(9):1503-7. PubMed ID: 3481217
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
[TBL] [Abstract][Full Text] [Related]
10. [Ofloxacin versus pipemidic acid and co-trimoxazole].
Wittenberger R
Infection; 1986; 14 Suppl 1():S93-6. PubMed ID: 3514474
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of ofloxacin (OFLX) on urinary tract infections].
Miyata M; Inagaki N; Inada F; Yachiku S; Okamura K; Osanai H; Mizunaga M; Morikawa M
Hinyokika Kiyo; 1987 Aug; 33(8):1303-11. PubMed ID: 3480688
[TBL] [Abstract][Full Text] [Related]
12. [Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].
Naber KG; Adam D; Bauernfeind A; Hönig E
Infection; 1986; 14 Suppl 2():S122-9. PubMed ID: 2428754
[TBL] [Abstract][Full Text] [Related]
13. The comparative pharmacokinetics of five quinolones.
Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
Bauernfeind A; Ullmann U
J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
Edlund C; Nord CE
Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
[TBL] [Abstract][Full Text] [Related]
16. The comparative in-vitro activity of ofloxacin.
Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
[TBL] [Abstract][Full Text] [Related]
17. [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].
Schulz W; Dörfler A
Infection; 1986; 14 Suppl 1():S97-101. PubMed ID: 3456988
[TBL] [Abstract][Full Text] [Related]
18. Ofloxacin vs. cotrimoxazole in patients with complicated urinary tract infections.
Vellucci A; Bernardini G; Battaglia AM; Battaglia P
Int J Clin Pharmacol Ther Toxicol; 1987 May; 25(5):279-81. PubMed ID: 3496284
[TBL] [Abstract][Full Text] [Related]
19. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
Bassey CM; Baltch AL; Smith RP
J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
Van der Auwera P
Infection; 1986; 14(3):142-4. PubMed ID: 2942489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
